ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of ADG106 With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03802955
Recruitment Status : Recruiting
First Posted : January 14, 2019
Last Update Posted : January 14, 2019
Sponsor:
Information provided by (Responsible Party):
Adagene Inc ( Adagene (Suzhou) Limited )

Brief Summary:

This is a Phase 1, open-label, dose-escalation, single-center study of ADG106 in subjects with advanced or metastatic solid tumors and/or relapsed/ refractory non-Hodgkin lymphoma. ADG106 is a fully human ligand-blocking, agonistic anti-CD137 IgG4 mAb. It binds to the activated human T cells via a T cell receptor CD137. T cell is a kind of lymphocyte (a subtype of white blood cells) that protects bodies by eliminating tumor cells, and normal cells infected with viruses or bacteria. By binding to CD137, the study drug is expected to enhance the activity of activated T cells and thus stimulate a more intense immune attack to kill tumor cells. ADG106 is expected to enhance the activity of activated T cells.

Primary objective:

To assess safety and tolerability at increasing dose levels of single agent ADG106 in subjects with advanced or metastatic solid tumors and/or non Hodgkin lymphoma.

To determine the recommended dosage and dosage regimen for further study. Secondary Objectives To characterize the pharmacokinetic (PK) profiles of ADG106. To evaluate the immunogenicity of ADG106. To evaluate the potential anti-tumor effect of ADG106. To investigate serum biomarkers related to immune regulation and cytokine releasing.

Exploratory Objective:

To identify the potential biomarkers of ADG106.


Condition or disease Intervention/treatment Phase
Solid Tumor Non-Hodgkin Lymphoma Drug: ADG106 Phase 1

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase Ⅰ Study of ADG106 Administered in Patients With Advanced or Metastatic Solid Tumors and/or Non-Hodgkin Lymphoma
Actual Study Start Date : December 20, 2018
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : December 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: ADG106 Dose escalation Drug: ADG106
IV infusion over 60 minutes on Day 1 of each cycle, at doses of 0.1 mg/kg, 0.5 mg/kg, 1.5 mg/kg, 3.0 mg/kg, 5.0 mg/kg, 7.5 mg/kg, or 10 mg/kg depending on cohort at enrollment.




Primary Outcome Measures :
  1. DLTs in the first 2 cycles of single drug administration [ Time Frame: 2 Cycles (42 days) ]

Secondary Outcome Measures :
  1. Number of clinical and laboratory adverse events (AEs) . [ Time Frame: First dose to 30 days post last dose ]
  2. Objective response rate (ORR) as assessed by RECIST version 1.1 and immune-related RECIST (irRECIST) for solid tumor and the Lugano Classification for non-Hodgkin Lymphoma [ Time Frame: 2 Cycles (42 days) ]
  3. Duration of response (DOR) as assessed by RECIST version 1.1 and immune-related RECIST (irRECIST) for solid tumor and the Lugano Classification for non-Hodgkin Lymphoma [ Time Frame: 2 Cycles (42 days) ]
  4. Time to progression (TTP) as assessed by RECIST version 1.1 and immune-related RECIST (irRECIST) for solid tumor and the Lugano Classification for non-Hodgkin Lymphoma [ Time Frame: 2 Cycles (42 days) ]
  5. Disease control rate (DCR) as assessed by RECIST version 1.1 and immune-related RECIST (irRECIST) for solid tumor and the Lugano Classification for non-Hodgkin Lymphoma [ Time Frame: 2 Cycles (42 days) ]
  6. Progression-free survival (PFS) as assessed by RECIST version 1.1 and immune-related RECIST (irRECIST) for solid tumor and the Lugano Classification for non-Hodgkin Lymphoma [ Time Frame: 2 Cycles (42 days) ]
  7. Peak plasma concentration (Cmax) [ Time Frame: 2 Cycles (42 days) ]
  8. Plasma concentration at the end of a dosing interval (Ctrough) [ Time Frame: 2 Cycles (42 days) ]
  9. Time to reach Cmax (Tmax) [ Time Frame: 2 Cycles (42 days) ]
  10. Area under the curve from time zero to the last timepoint (AUC0-last) [ Time Frame: 2 Cycles (42 days) ]
  11. AUC from time zero to infinity (AUC0-∞) [ Time Frame: 2 Cycles (42 days) ]
  12. AUC during a dosing interval (AUCtau) [ Time Frame: 2 Cycles (42 days) ]
  13. Clearance (CL) [ Time Frame: 2 Cycles (42 days) ]
  14. Volume of distribution at steady state (Vss) [ Time Frame: 2 Cycles (42 days) ]
  15. ADA levels for ADG106. [ Time Frame: 2 Cycles (42 days) ]
  16. Serum biomarkers linked to immunomodulation and cytokine release: such as TNFα, IFN-γ, IL 10, IL-6, IL-4, IL-2. [ Time Frame: 2 Cycles (42 days) ]
  17. Cell counts for circulating T, natural killer (NK), and B cells. [ Time Frame: 2 Cycles (42 days) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male or female, 18 years to 75 years of age at the time of consent.
  2. Provide written informed consent.
  3. Subjects with advanced and/or metastatic histologically or cytologically confirmed solid tumor and/or non-Hodgkin lymphoma who are refractory or relapsed from standard therapy and who have exhausted all available therapies.
  4. Provide tumor pathological section to the third party lab for PD-L1, CD137, CD137-L, MSI testing during screening period
  5. At least one measurable lesion per RECIST 1.1 for solid tumors and per Lugano Classification for non-Hodgkin lymphoma
  6. ECOG performance: 0-1
  7. Adequate organ and bone marrow function
  8. After receiving the last treatment (chemotherapy, radiotherapy, biotherapy or other research drugs), the patient had a washout period of at least 4 weeks or more than 5 half-lives, and had recovered from any toxic reaction of the previous treatment to less than 1 degree.
  9. No other concomitant antineoplastic therapy (including cell therapy)
  10. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within the 7 days prior to study drug administration.
  11. Coagulation function is basically normal, INR≤1.5
  12. Cooperative in observation of adverse events and efficacy

Exclusion Criteria:

  1. Subjects with positive HCV antibody,or active hepatitis B (HBV DNA ≥ 10000 copies/mL or 2000 IU/mL), or positive hepatitis virus and taking antiviral drugs
  2. Subjects with meningeal metastasis, or subjects with brain metastasis lesions ≥ 1 cm and untreated, or subjects with brain metastasis requiring mannitol or other dehydration therapy
  3. Infection of human immunodeficiency virus (HIV), or suffering from other acquired, congenital immunodeficiency disorders, or organ transplantation history
  4. Any active autoimmune disease or evidence-based autoimmune disease, or systemic syndrome requiring systemic steroids or immunosuppressive drugs (Except for inactive vitiligo, psoriasis, asthma/specific reactivity in children after treatment within two years, or thyroid diseases controlled by alternative therapy/non-immunosuppressive therapy)
  5. The residual toxicity of the patient's previous treatment was more than grade 1
  6. Fever body temperature above 38℃ or there are clinically obvious active infections that can affect clinical trials
  7. Overdose of glucocorticoid (>10mg/d prednisone or equivalent dose) or other immunosuppressive agents was used within one month
  8. According to the investigator, any uncontrollable serious clinical problems include but are not limited to, evidence of severe or uncontrollable systemic diseases (such as unstable or uncompensated respiratory, cardiac, liver or kidney diseases); and any unstable systemic diseases (including active infections, refractory high or drug failure Controlled hypertension (>150/100 mmHg), unstable angina pectoris, congestive heart failure, liver and kidney or metabolic diseases)
  9. A clear history of neurological or psychiatric disorders, including epilepsy or dementia
  10. Non-research-related surgical procedures performed prior to the use of research drugs in patients within 28 days
  11. Investigator do not consider he/she appropriate to participate in this study
  12. Pregnant or lactating women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03802955


Contacts
Contact: Xiaohong She, Master +8618260157039 kristine_she@adagene.com

Locations
China, Guangdong
Sun Yat-sen University Cancer Center Recruiting
Guangzhou, Guangdong, China, 510000
Contact: Li Zhang, Master         
Sponsors and Collaborators
Adagene (Suzhou) Limited

Responsible Party: Adagene (Suzhou) Limited
ClinicalTrials.gov Identifier: NCT03802955     History of Changes
Other Study ID Numbers: ADG106-1002
First Posted: January 14, 2019    Key Record Dates
Last Update Posted: January 14, 2019
Last Verified: January 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Adagene Inc ( Adagene (Suzhou) Limited ):
Solid Tumor
Non-Hodgkin Lymphoma

Additional relevant MeSH terms:
Lymphoma
Lymphoma, Non-Hodgkin
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases